伴侣动物药品市场－全球产业规模、份额、趋势、机会和预测，依适应症、动物种类、配销通路、地区和竞争格局划分，2020-2030年预测

2024年全球伴侣动物药品市场规模为185.2亿美元，预计2030年将以9.25%的复合年增长率成长至314.9亿美元。该市场涵盖用于治疗、预防和控制宠物疾病的药品和生物製品，包括药物、疫苗和营养补充剂。推动该市场成长的主要因素包括：宠物饲养量的增加、宠物人性化趋势的显着发展导致宠物健康支出增加、宠物主人预防保健意识的提高以及兽医学的不断进步。

主要市场驱动因素

全球宠物饲养量的不断增长以及宠物日益拟人化，是推动伴侣动物药品市场发展的重要因素。宠物主人越来越将宠物视为家庭成员，因此也更愿意在宠物的健康和福祉方面投入大量资金。

主要市场挑战

全球伴侣动物药品市场扩张面临的一大挑战是研发成本高昂，加之严格的监管要求和漫长的兽药审批流程，使得情况雪上加霜。这些因素共同阻碍了持续投资，延长了创新疗法进入市场的时间，从而影响了该行业有效应对伴侣动物不断变化的健康需求的能力。

主要市场趋势

生物製剂和先进疗法的日益普及标誌着伴侣动物药物领域的深刻变革，使其超越了传统的小分子药物，转向更具标靶性的干预措施。这些创新疗法，包括单株抗体和基因疗法，在治疗慢性复杂疾病（例如骨关节炎和各种癌症）方面，展现出更高的疗效和精准度。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球伴侣动物药品市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症分类（传染病、皮肤病、疼痛、骨科疾病、行为疾病、其他）
  • 依动物分类（狗、猫、马、其他）
  • 按配销通路（兽医院和诊所、零售药局、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美伴侣动物药品市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲伴侣动物药品市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区伴侣动物药品市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲伴侣动物药品市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美伴侣动物药品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球伴侣动物药品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Zoetis Services LLC
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• Virbac Taiwan Co., Ltd.
• Vetoquinol SA
• Dechra Pharmaceuticals Limited
• Chanelle Pharma
• KyoritsuSeiyaku Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global Companion Animal Pharmaceuticals Market, valued at USD 18.52 Billion in 2024, is projected to experience a CAGR of 9.25% to reach USD 31.49 Billion by 2030. The global companion animal pharmaceuticals market encompasses pharmaceutical and biological products developed to treat, prevent, and manage diseases in pets, including medications, vaccines, and supplements. This market's growth is primarily driven by increasing pet ownership, the notable trend of pet humanization leading to higher spending on animal health, rising awareness among owners regarding preventive care, and continuous advancements in veterinary medical science.

Key Market Drivers

The increasing global trend of pet ownership coupled with the growing humanization of pets represents a foundational driver for the companion animal pharmaceuticals market. Pet owners increasingly view their animals as integral family members, leading to a willingness to invest significantly in their health and well-being. This shift elevates the standard of care provided to pets, encompassing advanced medical treatments, preventive medications, and specialized therapies.

Key Market Challenges

A significant challenging factor impeding the expansion of the Global Companion Animal Pharmaceuticals Market involves the substantial costs associated with research and development, compounded by stringent regulatory requirements and a protracted approval process for new veterinary drugs. These elements collectively deter sustained investment and prolong the market entry of innovative treatments, thereby impacting the industry's capacity to effectively address the evolving health needs of companion animals. This extended development pipeline can delay critical advancements in medications, vaccines, and supplements.

Key Market Trends

The growing adoption of biologics and advanced therapeutics signifies a profound evolution in companion animal pharmaceuticals, moving beyond traditional small-molecule drugs to more targeted interventions. These innovative treatments, including monoclonal antibodies and gene therapies, offer enhanced efficacy and precision in managing chronic and complex diseases, such as osteoarthritis and various cancers. Their ability to address unmet medical needs by targeting specific disease pathways is driving demand.

Key Market Players

• Zoetis Services LLC
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• Virbac Taiwan Co., Ltd.
• Vetoquinol S.A.
• Dechra Pharmaceuticals Limited
• Chanelle Pharma
• KyoritsuSeiyaku Corporation

Report Scope:

In this report, the Global Companion Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Animal Pharmaceuticals Market, By Indication:

• Infectious diseases
• Dermatologic diseases
• Pain
• Orthopedic diseases
• Behavioural diseases
• Other

Companion Animal Pharmaceuticals Market, By Animal:

• Dogs
• Cats
• Horses
• Other

Companion Animal Pharmaceuticals Market, By Distribution Channel:

• Veterinary hospitals and clinics
• Retail pharmacies
• Others

Companion Animal Pharmaceuticals Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Companion Animal Pharmaceuticals Market.

Available Customizations:

Global Companion Animal Pharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Companion Animal Pharmaceuticals Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Infectious diseases, Dermatologic diseases, Pain, Orthopedic diseases, Behavioural diseases, Other)
  • 5.2.2. By Animal (Dogs, Cats, Horses, Other)
  • 5.2.3. By Distribution Channel (Veterinary hospitals and clinics, Retail pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Companion Animal Pharmaceuticals Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Animal
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Companion Animal Pharmaceuticals Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Animal
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Companion Animal Pharmaceuticals Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Animal
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Companion Animal Pharmaceuticals Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Animal
      • 6.3.3.2.3. By Distribution Channel

7. Europe Companion Animal Pharmaceuticals Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Animal
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Companion Animal Pharmaceuticals Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Animal
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Companion Animal Pharmaceuticals Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Animal
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Companion Animal Pharmaceuticals Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Animal
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Companion Animal Pharmaceuticals Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Animal
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Companion Animal Pharmaceuticals Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Animal
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Companion Animal Pharmaceuticals Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Animal
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Companion Animal Pharmaceuticals Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Animal
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Companion Animal Pharmaceuticals Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Animal
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Companion Animal Pharmaceuticals Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Animal
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Companion Animal Pharmaceuticals Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Animal
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Companion Animal Pharmaceuticals Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Animal
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Companion Animal Pharmaceuticals Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Animal
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Companion Animal Pharmaceuticals Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Animal
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Companion Animal Pharmaceuticals Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Animal
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Companion Animal Pharmaceuticals Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Animal
      • 9.3.3.2.3. By Distribution Channel

10. South America Companion Animal Pharmaceuticals Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Animal
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Companion Animal Pharmaceuticals Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Animal
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Companion Animal Pharmaceuticals Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Animal
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Companion Animal Pharmaceuticals Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Animal
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Companion Animal Pharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Services LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Boehringer Ingelheim International GmbH
• 15.4. Elanco Animal Health Incorporated
• 15.5. Virbac Taiwan Co., Ltd.
• 15.6. Vetoquinol S.A.
• 15.7. Dechra Pharmaceuticals Limited
• 15.8. Chanelle Pharma
• 15.9. KyoritsuSeiyaku Corporation

16. Strategic Recommendations

17. About Us & Disclaimer